CD274 and neoplasm: Preclinical studies suggest that nab-paclitaxel may exert immunomodulatory effects, such as enhancing dendritic cell activation and promoting tumor antigen presentation, which could synergize with PD-1/PD-L1 blockade to amplify antitumor responses (11).